| | Author | Study design | Number of patients (n) | Duration | Agent | Response | Bleeding events |
| Janczak [19]
(2018) | Prospective, non-cirrhotic,
Atypical sites | Total
N=36
PVT
N= 16 | | Rivaroxaban
Apixaban
| Recurrence rate
7.3 % (n=2)
(both had malignancy) | Minor
N=1 (3.6%)
Major
N=2 (7.2%) |
| Qi [20]
(2017) | Case report, cirrhotic, CPT not specified | SMV, splenic vein, N=1 | 11 weeks | Rivaroxaban | Recanalization | Melena and hematemesis |
| Nery [21]
(2017) | Case report
Non-cirrhotic | N=1 | >6m | Rivaroxaban 20 mg daily | Complete recanalization L branch,
partial recanalization right branch | None |
| De Gottardi [10]
(2016) | Retrospective, Both cirrhotic and non-cirrhotic,
Splanchnic | Total,
N= 94
PVT
N= 80
(Non cirrh-
N=38
Cirrh-
N=22) | Non-cirrhotic
13.1 m
cirrhotic
9.6 m | Rivaroxaban
Apixaban
Dabigatran
| Not studied | Cirrhosis:
Minor, n=7, Major, n=2
Non-cirrh:
Minor,
n= 4
Major, n=1 |
| Hum [9]
(2016) | Retrospective,
Cirrhotic,
CPT A, B & C
All indications | Total,
N= 27
PVT
N=4 | | Rivaroxaban
15 mg bid
+/- 20 mg daily load,
Apixaban
5mg bid +/- 10mg bid load, No bridging | Recurrence rate 4%
(n=1) | Major
N=1 (4%)
Minor,
N=7 |
| Yang [12]
(2016) | Case report, cirrhotic
CPT A | N=1 | 6 m | Rivaroxaban
15 mg bid x 3 wks, then 20 mg/d | Complete recanalization | None |
| Intagliata [8]
(2015) | Retrospective, cirrhotic,
CPT A and B | Total
N= 20
PVT, N=12 | 10.6 m | Apixaban
Rivaroxaban | Not studied | Major, n=1
|
| Martinez [22]
(2014) | Case report,
Cirrhotics,
CPT A | N=1 | 6 m | Rivaroxaban
20 mg /d | Complete recanalization | None |
| Lenz [11]
(2014) | Case report,
Cirrhotic
CPT A | N=1 | 5 m | Rivaroxaban 10 mg daily | Complete recanalization | None |
| Pannach [23]
(2013) | Case report,
Non-cirrhotic | N=1 | >4 weeks | Rivaroxaban 20 mg daily | Complete recanalization | None |
|
|
